This journal club discusses the AVOID study, which investigated whether supplemental oxygen therapy increases myocardial infarct size in normoxic patients with ST-segment elevation myocardial infarction (STEMI). The randomized controlled trial of 441 patients found that routine oxygen administration was not associated with reduced symptoms but was accompanied by harm, as reflected by a significant rise in CK levels and larger infarct size on cardiac MRI at 6 months, compared to patients who did not receive supplemental oxygen. The study suggests that routine supplemental oxygen for normoxic STEMI patients may do more harm than good.
Related topics: